kabutan

KAKEN PHARMA, First Half Ordinary Profit Decreases by 97%, Jul-Sep Ordinary Profit Decreases by 99%

Mon Nov 10, 2025 3:30 pm JST Earnings

4521 KAKEN PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Earnings Report

KAKEN PHARMACEUTICAL CO.,LTD. <4521> [TSE Prime] announced its financial results after the market closed on November 10th (15:30). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending March 2026 (April to September) significantly dropped 96.9% from the same period last year to 0.60 billion yen. Progress toward the full-year plan of 2.80 billion yen was 21.7%, also falling below the five-year average of 71.3%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the October to March period (second half) is expected to expand 50.6% from the same period last year, reaching 2.19 billion yen.

In the most recent three-month period, from July to September (2Q), the consolidated ordinary profit significantly dropped to 0.19 billion yen, a 98.9% decrease compared to the same period last year. The operating profit margin sharply declined from 50.8% in the same period last year to 0.9%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2023 36,171 5,512 5,722 4,068 108.2 57.5 Nov 8, 2023 J-GAAP
Apr - Sep, 2024 51,372 19,579 19,823 14,286 377.2 93.2 Nov 8, 2024 J-GAAP
Apr - Sep, 2025 39,356 203 607 992 26.2 21.7 Nov 10, 2025 J-GAAP
YoY -23.4% -99.0% -96.9% -93.1% -93.1%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 Guidance ー ー ー ー － 95 May 12, 2025 J-GAAP
Apr - Sep, 2025 Results 39,356 203 607 992 26.2 95 Nov 10, 2025 J-GAAP
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 42,663 1,455 1,456 -341 -8.9 75 May 12, 2025 J-GAAP
Oct - Mar, 2025 Guidance 46,944 1,897 2,193 1,308 34.5 95 Nov 10, 2025 J-GAAP
YoY +10.0% +30.4% +50.6% － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 72,044 9,513 9,951 8,025 212.7 150 May 14, 2024 J-GAAP
Mar, 2025 94,035 21,034 21,279 13,945 365.4 190 May 12, 2025 J-GAAP
Mar, 2026 Guidance 86,300 2,100 2,800 2,300 60.7 190 Sep 26, 2025 J-GAAP
YoY -8.2% -90.0% -86.8% -83.5% -83.4%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2024 33,118 16,829 16,812 12,532 330.9 50.8 Nov 8, 2024 J-GAAP
Oct - Dec, 2024 24,618 5,841 6,258 4,889 129.1 23.7 Feb 6, 2025 J-GAAP
Jan - Mar, 2025 18,045 -4,386 -4,802 -5,230 -137.1 -24.3 May 12, 2025 J-GAAP
Apr - Jun, 2025 18,867 14 417 271 7.1 0.1 Aug 7, 2025 J-GAAP
Jul - Sep, 2025 20,489 189 190 721 19.0 0.9 Nov 10, 2025 J-GAAP
YoY -38.1% -98.9% -98.9% -94.2% -94.3%

Related Articles